Questionable validity of cardiac risk score on the basis of the NSABP B-31 model

Comment

Vincenzo Pitini et al. J Clin Oncol. 2013.

. 2013 Jun 10;31(17):2224.

doi: 10.1200/JCO.2012.47.2696. Epub 2013 May 6.

No abstract available

Comment in

Reply to V. Pitini et al.
Romond EH, Rastogi P, Jeong JH. Romond EH, et al. J Clin Oncol. 2013 Jun 10;31(17):2225. doi: 10.1200/JCO.2012.48.3701. J Clin Oncol. 2013. PMID: 23901419 No abstract available.
Reply to V. Pitini et al.
Mayer EL, Lin NU. Mayer EL, et al. J Clin Oncol. 2013 Jun 10;31(17):2225-6. doi: 10.1200/JCO.2012.48.3719. J Clin Oncol. 2013. PMID: 23901420 No abstract available.

Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.
Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CE Jr, Ewer MS, Rathi V, Fehrenbacher L, Brufsky A, Azar CA, Flynn PJ, Zapas JL, Polikoff J, Gross HM, Biggs DD, Atkins JN, Tan-Chiu E, Zheng P, Yothers G, Mamounas EP, Wolmark N. Romond EH, et al. J Clin Oncol. 2012 Nov 1;30(31):3792-9. doi: 10.1200/JCO.2011.40.0010. Epub 2012 Sep 17. J Clin Oncol. 2012. PMID: 22987084 Free PMC article. Clinical Trial.
Long term follow-up of national surgical adjuvant breast and bowel project trial B-31: how well can we predict cardiac toxicity with trastuzumab?
Mayer EL, Lin NU. Mayer EL, et al. J Clin Oncol. 2012 Nov 1;30(31):3769-72. doi: 10.1200/JCO.2012.44.9611. Epub 2012 Sep 17. J Clin Oncol. 2012. PMID: 22987088 No abstract available.